SQZ Biotechnologies Return on Investment 2020-2022 | SQZ

Current and historical return on investment (ROI) values for SQZ Biotechnologies (SQZ) over the last 10 years.
SQZ Biotechnologies ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2022-03-31 $-0.07B inf%
2021-12-31 $-0.07B inf%
2021-09-30 $-0.07B inf%
2021-06-30 $-0.06B inf%
2021-03-31 $-0.06B inf%
2020-12-31 $-0.05B inf%
2020-06-30 $-0.03B inf%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.087B $0.027B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00